|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...910111213141516171819...6566» |
- New trial: Evaluation of Systemic Microvascular Endothelial Dysfunction in Patients Presenting With Infective Endocarditis (clinicaltrials.gov) - Oct 20, 2016
P=N/A, N=50, Recruiting, Sponsor: National Institute of Cardiology, Laranjeiras, Brazil
- |||| Enrollment open, Trial initiation date: A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001) (clinicaltrials.gov) - Oct 20, 2016
P2, N=113, Recruiting, Sponsor: Global Alliance for TB Drug Development
Not yet recruiting --> Recruiting | Initiation date: Aug 2016 --> Nov 2014
- |||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Trial primary completion date: Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine (clinicaltrials.gov) - Oct 19, 2016
P3, N=793, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting | Initiation date: Aug 2016 --> Nov 2014 Trial primary completion date: Oct 2008 --> May 2008
- | clindamycin phosphate / Generic mfg.
Trial completion: CLIN01: Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile (clinicaltrials.gov) - Oct 19, 2016
P1, N=22, Completed, Sponsor: Phillip Brian Smith
Trial primary completion date: Oct 2008 --> May 2008 Active, not recruiting --> Completed
- ||||| VivaGel (astodrimer vaginal) / Starpharma
Enrollment closed, Trial primary completion date: Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV) (clinicaltrials.gov) - Oct 17, 2016
P3, N=620, Active, not recruiting, Sponsor: Starpharma Pty Ltd
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2015 --> Jan 2017
- | New P4 trial: Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment (clinicaltrials.gov) - Oct 16, 2016
P4, N=500, Not yet recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- azithromycin / Generic mfg.
Trial completion, Phase classification, Enrollment change: Macrolide Mediates Pulmonary Infection of Pseudomonas Aeruginosa (clinicaltrials.gov) - Oct 14, 2016
P=N/A, N=71, Completed, Sponsor: Jin-Fu Xu
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2015 --> Jan 2017 Recruiting --> Completed | Phase classification: P4 --> PN/A | N=50 --> 71
- Trial completion, Enrollment change, Surgery: PCR Technique to Identify Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus in Nasal and Respiratory Tract Samples (clinicaltrials.gov) - Oct 14, 2016
P=N/A, N=200, Completed, Sponsor: Emilio Bouza
Recruiting --> Completed | Phase classification: P4 --> PN/A | N=50 --> 71 Recruiting --> Completed | N=300 --> 200
- |||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Trial primary completion date, Pneumococcal vaccines: Prophylactic Antipyretic Treatment in Children Receiving Booster Dose of Pneumococcal Conjugate Vaccine GSK1024850A (clinicaltrials.gov) - Oct 12, 2016
P3, N=750, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed | N=300 --> 200 Trial primary completion date: Feb 2009 --> Mar 2008
- | Synflorix (10-valent pneumococcal conjugate vaccine) / GSK
Phase classification, IO biomarker, Pneumococcal vaccines: Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population (clinicaltrials.gov) - Oct 12, 2016
P1/2, N=335, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Feb 2009 --> Mar 2008 Phase classification: P1 --> P1/2
- Enrollment open: PCS: Preventing Congenital Syphilis (clinicaltrials.gov) - Oct 11, 2016
P=N/A, N=6000, Recruiting, Sponsor: Tulane University School of Public Health and Tropical Medicine
Phase classification: P1 --> P1/2 Not yet recruiting --> Recruiting
- | Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health, Norgine, ASKA Pharma
Enrollment change, Trial termination, Trial primary completion date: VARIANT: Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis (clinicaltrials.gov) - Oct 11, 2016
P2, N=392, Terminated, Sponsor: Alfa Wassermann S.p.A.
Not yet recruiting --> Recruiting N=626 --> 392 | Recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Feb 2016; According to the Recommendation of the Indipendent Data Monitoring Committee
- ||| Enrollment open: PALUBAC: Optimizing Sysmex Technology as an Innovative Tool to Differentiate Between Malaria (PALUdism) and BACterial Infections in a Malaria Endemic Region (clinicaltrials.gov) - Oct 11, 2016
P=N/A, N=1250, Recruiting, Sponsor: Sysmex Europe GmbH
N=626 --> 392 | Recruiting --> Terminated | Trial primary completion date: Oct 2015 --> Feb 2016; According to the Recommendation of the Indipendent Data Monitoring Committee Not yet recruiting --> Recruiting
- Trial completion: Cerebral Antibiotics Distribution After Acute Brain Injury (clinicaltrials.gov) - Oct 11, 2016
P1, N=18, Completed, Sponsor: Poitiers University Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed
- Hutruo (bermekimab IV) / J&J
Enrollment closed: MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB (clinicaltrials.gov) - Oct 11, 2016
P2, N=20, Active, not recruiting, Sponsor: Evangelos J. Giamarellos-Bourboulis, M.D.
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Enrollment open: A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults (clinicaltrials.gov) - Oct 7, 2016
P1, N=63, Recruiting, Sponsor: LG Life Sciences
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- colchicine / Generic mfg.
Enrollment change, Trial withdrawal, Adverse events: The Effect of Probiotics on Response to Therapy and on Adverse Effect in Patients Treated With Colchicine for Familial Mediterranean Fever. (clinicaltrials.gov) - Oct 7, 2016
P=N/A, N=0, Withdrawn, Sponsor: Rambam Health Care Campus
Not yet recruiting --> Recruiting N=20 --> 0 | Not yet recruiting --> Withdrawn
- ||| ribaxamase (SYN-004) / Synthetic Biologics
Enrollment closed: A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI (clinicaltrials.gov) - Oct 7, 2016
P2, N=372, Active, not recruiting, Sponsor: Synthetic Biologics Inc.
N=20 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- Shanchol (oral cholera vaccine) / Sanofi
Enrollment open, Head-to-Head: Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine (clinicaltrials.gov) - Oct 7, 2016
P2, N=2052, Recruiting, Sponsor: International Centre for Diarrhoeal Disease Research, Bangladesh
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Trial completion: Could the Stroke Volume Variation Predict a Fluid Responsiveness in Thoracotomy? (clinicaltrials.gov) - Oct 7, 2016
P=N/A, N=79, Completed, Sponsor: Samsung Medical Center
Not yet recruiting --> Recruiting Recruiting --> Completed
- |||| Nimenrix (MenACWY-TT) / Pfizer
Trial completion: Study in Children to Evaluate the Immunogenicity and Safety of 4 Formulations of GSK Bio MenACWY-TT Conjugate Vaccine (clinicaltrials.gov) - Oct 6, 2016
P2, N=508, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed No longer recruiting --> Completed
- |||| PF-06290510 / Pfizer
Trial completion: SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults (clinicaltrials.gov) - Oct 6, 2016
P2, N=136, Completed, Sponsor: Pfizer
No longer recruiting --> Completed Active, not recruiting --> Completed
- New trial, Adherence: Study Medication Adherence and Its Determinants in Chronic Disease Through the Example of Methotrexate in Chronic Inflammatory Rheumatism (clinicaltrials.gov) - Oct 6, 2016
P=N/A, N=100, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
- Trial completion, Enrollment change: Evaluation of a LAM FLISA for the Diagnosis of Tuberculosis (clinicaltrials.gov) - Oct 6, 2016
P=N/A, N=92, Completed, Sponsor: Research Center Borstel
Active, not recruiting --> Completed Suspended --> Completed | N=130 --> 92
- New trial: Primary Antimicrobial Resistance Patterns of Austrian Helicobacter Pylori Clinical Isolates (clinicaltrials.gov) - Oct 5, 2016
P=N/A, N=2000, Completed, Sponsor: Medical University of Vienna
- | Nuvocid (oritavancin) / Melinta Therap
New P4 trial: Safety of Either a Single or Two IV Doses of Orbactiv in Subjects With ABSSSI (clinicaltrials.gov) - Oct 5, 2016
P4, N=20, Not yet recruiting, Sponsor: The Medicines Company
- | PnuBioVax (PBV) / ImmunoBiology
Trial completion: A Phase I Study to Evaluate the Safety and Immunogenicity of PnuBioVax (clinicaltrials.gov) - Oct 5, 2016
P1, N=36, Completed, Sponsor: ImmunoBiology Limited
Suspended --> Completed | N=130 --> 92 Active, not recruiting --> Completed
- Gatiflox (gatifloxacin) / Orient Europharma
Trial completion, Head-to-Head: Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever (clinicaltrials.gov) - Oct 4, 2016
P4, N=300, Completed, Sponsor: Oxford University Clinical Research Unit, Vietnam
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Zemdri (plazomicin) / Ionis, Achaogen
Trial completion: A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE) (clinicaltrials.gov) - Oct 4, 2016
P3, N=69, Completed, Sponsor: Achaogen, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Zemdri (plazomicin) / Ionis, Achaogen
Trial completion: EPIC: A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) (clinicaltrials.gov) - Oct 4, 2016
P3, N=609, Completed, Sponsor: Achaogen, Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- CTH522 / Statens Serum Institut, Imperial College London
Enrollment open: Safety of Chlamydia Vaccine CTH522 in Healthy Women Aged 18 to 45 Years (clinicaltrials.gov) - Oct 3, 2016
P1, N=35, Recruiting, Sponsor: Statens Serum Institut
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Trial completion, Pneumococcal vaccines: The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine (clinicaltrials.gov) - Oct 3, 2016
P4, N=162, Completed, Sponsor: Kameda Medical Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- |||| gepotidacin (GSK2140944) / GSK
Trial completion: A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae (clinicaltrials.gov) - Sep 30, 2016
P2, N=106, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Recruiting --> Completed
- |||| Privigen (human immune globulin intravenous 10%) / CSL Behring
Trial completion: INSTINCT: Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial (clinicaltrials.gov) - Sep 30, 2016
P2, N=100, Completed, Sponsor: Anders Perner
Recruiting --> Completed Active, not recruiting --> Completed
- Phase classification: Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid (clinicaltrials.gov) - Sep 28, 2016
P2b, N=45, Completed, Sponsor: California Department of Public Health
Active, not recruiting --> Completed Phase classification: P2 --> P2b
- Trial completion, Enrollment change, Trial primary completion date: Implementation of a Sexual Health Intervention for Young Men Who Have Sex With Men (MSM) in Two Vietnamese Cities (clinicaltrials.gov) - Sep 28, 2016
P=N/A, N=1166, Completed, Sponsor: National Development and Research Institutes, Inc.
Phase classification: P2 --> P2b Recruiting --> Completed | N=1500 --> 1166 | Trial primary completion date: Feb 2017 --> Sep 2016
- Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine) / GSK, Adacel (tetanus toxoid/reduced diphtheria toxoid/acellular pertussis vaccine adsorbed) / Sanofi
Trial primary completion date: Mutliboost: Pertussis and Meningitis C Concomitant Vaccination in Adolescents (clinicaltrials.gov) - Sep 28, 2016
P4, N=800, Recruiting, Sponsor: Public Health England
Recruiting --> Completed | N=1500 --> 1166 | Trial primary completion date: Feb 2017 --> Sep 2016 Trial primary completion date: Aug 2016 --> Dec 2016
- New trial: Effect of Passive Ultrasonic Irrigation on the Reduction of Bacteria and Endotoxins in Root Canals (clinicaltrials.gov) - Sep 28, 2016
P=N/A, N=40, Active, not recruiting, Sponsor: University of Sao Paulo
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: PIONEER (OLE): Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Sep 28, 2016
P3, N=510, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Trial primary completion date: Aug 2016 --> Dec 2016 Active, not recruiting --> Completed
- ||| MTBVAC / Zendal Group
Enrollment closed, Trial primary completion date, IO biomarker: MTBVAC-Ph1b: Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults (clinicaltrials.gov) - Sep 26, 2016
P1/2, N=54, Active, not recruiting, Sponsor: Biofabri, S.L
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Mar 2017
- Enrollment closed: TDAP Safety in Pregnant Women (clinicaltrials.gov) - Sep 23, 2016
P=N/A, N=375, Active, not recruiting, Sponsor: Vanderbilt University
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Mar 2017 Recruiting --> Active, not recruiting
- New trial: Prospective Assessment of TBDx Feasibility (clinicaltrials.gov) - Sep 23, 2016
P=N/A, N=572, Completed, Sponsor: Foundation for Innovative New Diagnostics, Switzerland
- ciprofloxacin oral / Generic mfg.
Trial initiation date, Trial primary completion date: Ciprofloxacin for the Prevention of Meningococcal Meningitis (clinicaltrials.gov) - Sep 22, 2016
P4, N=300, Not yet recruiting, Sponsor: Epicentre
Recruiting --> Active, not recruiting Initiation date: Apr 2016 --> Jan 2017 | Trial primary completion date: Jul 2016 --> May 2017
- Trial completion, Enrollment change: Anti-Pseudomonas Immune Status and Dendritic Cell Preparation in Normal Individuals (clinicaltrials.gov) - Sep 21, 2016
P=N/A, N=8, Completed, Sponsor: Weill Medical College of Cornell University
Initiation date: Apr 2016 --> Jan 2017 | Trial primary completion date: Jul 2016 --> May 2017 Withdrawn --> Completed | N=60 --> 8
- |||| Trial completion: Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs (clinicaltrials.gov) - Sep 20, 2016
P2, N=125, Completed, Sponsor: GlaxoSmithKline
Withdrawn --> Completed | N=60 --> 8 Recruiting --> Completed
- ||||| Zemdri (plazomicin) / Ionis, Achaogen
Enrollment closed, Trial primary completion date: EPIC: A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) (clinicaltrials.gov) - Sep 16, 2016
P3, N=609, Active, not recruiting, Sponsor: Achaogen, Inc.
Recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Sep 2016
- | Phase classification: Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) (clinicaltrials.gov) - Sep 16, 2016
P4, N=460, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Sep 2016 Phase classification: P3 --> P4
- Enrollment open: Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection (clinicaltrials.gov) - Sep 15, 2016
P4, N=200, Recruiting, Sponsor: Zahra Vahdat Shariatpanahi
Phase classification: P3 --> P4 Not yet recruiting --> Recruiting
- ||| Enrollment open, Trial initiation date: A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults (clinicaltrials.gov) - Sep 15, 2016
P1, N=144, Recruiting, Sponsor: Jiangsu Province Centers for Disease Control and Prevention
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Sep 2016
- || Trial primary completion date: Detection of Chlamydia (CT) and Gonorrhea (NG) (clinicaltrials.gov) - Sep 14, 2016
P=N/A, N=700, Active, not recruiting, Sponsor: Meridian Bioscience, Inc.
Not yet recruiting --> Recruiting | Initiation date: Jun 2016 --> Sep 2016 Trial primary completion date: Oct 2014 --> Dec 2016